Home
BNC KOREA

BNC KOREA Market Share Analysis for August 2026

설명한국비엔씨는 대한민국의 바이오 기업이다. 본사는 대구광역시 달서구 성서공단로11길 62 1호관 405호에 위치해 있으며 대표이사는 최완규이다. 위키백과

Health > Medicine

Domainbnckorea.co.kr

Year Founded2007

Employees51 - 200

Annual Revenue--

BNC KOREA

BNC KOREA (including company regionals)

bnckorea.co.kr

See more website traffic and engagement information

Total visits to BNC KOREA's top domains

Understand BNC KOREA market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

bnckorea.co.kr10K

See more with Sales Intelligence

Avg. visit duration in BNC KOREA's top domains

Analyze BNC KOREA engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

bnckorea.co.kr00:00:26

See more with Sales Intelligence

Avg. pageviews on BNC KOREA's top domains

See how BNC KOREA keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

bnckorea.co.kr1.80

See more with Sales Intelligence

BNC KOREA top competitors by domain

Top similar sites in August 2026, ranked by their affinity

bnc.ncCompany NameBNC - Bolsa Nacional de ComprasEmployees51 - 200HQBrazil, Ponta GrossaAnnual revenue--Total visits2.1KFinance > Financial Planning and Management

Top technologies used by BNC KOREA

These are the website technologies, by industry, used by BNC KOREA top domains

Mobile (1)

Meta Viewport

News & Signals from BNC KOREA

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsBnc Korea attended event BEAUTY ISTANBUL 2026 on May 1st '25.Last May, I.st participated in BEAUTY ISTANBUL 2026, a leading global B2B beauty exhibition representing Türkiye, Africa, and the CIS region, where the brand introduced an integrated beauty solution combining its PDRN skincare line with homecare beauty devices.

NewsBnc Korea is developing GLP1 agonist for treating diabetes and obesity using mRNA technology on Feb 8th '24.BNC Korea said Thursday that it has signed a joint research and development agreement with SML Biopharm to develop a GLP1 agonist for treating diabetes and obesity using mRNA technology.